ReviewDiscover oncology2025
Radiomics in pediatric brain tumors: from images to insights.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Radiomics: Current Applications and Future Directions.MedComm · 2026Review
- Editorial: Advancing cancer imaging technologies: bridging the gap from research to clinical practice.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiomics has emerged as a promising non-invasive imaging approach in pediatric neuro-oncology, offering the ability to extract high-dimensional quantitative features from routine MRI to support diagnosis, risk stratification, molecular characterization, and outcome prediction. Pediatric brain tumors, which differ significantly from adult tumors in biology and imaging appearance, present unique diagnostic and prognostic challenges. By integrating radiomics with machine learning algorithms, studies have demonstrated strong performance in classifying tumor types such as medulloblastoma, ependymoma, and gliomas, and predicting molecular subgroups and mutations such as H3K27M and BRAF. Recent studies combining radiomics with machine learning algorithms - including support vector machines, random forests, and deep learning CNNs - have demonstrated promising performance, with AUCs ranging from 0.75 to 0.98 for tumor classification and 0.77 to 0.88 for molecular subgroup prediction, across cohorts from 50 to over 450 patients, with internal cross-validation and external validation in some cases. In resource-limited settings or regions with limited radiologist manpower, radiomics-based tools could help augment diagnostic accuracy and consistency, serving as decision support to prioritize patients for further evaluation or biopsy. Emerging applications such as radio-immunomics and radio-pathomics may further enhance understanding of tumor biology but remain investigational. Despite its potential, clinical translation faces notable barriers, including limited pediatric-specific datasets, variable imaging protocols, and the lack of standardized, reproducible workflows. Multi-institutional collaboration, harmonized pipelines, and prospective validation are essential next steps. Radiomics should be viewed as a supplementary tool that complements existing clinical and pathological frameworks, supporting more informed and equitable care in pediatric brain tumor management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.